Calcitonin Pre-treatment to Improve SPECT-CT Sensitivity

Description

Patients with biochemically confirmed primary hyperparathyroidism and non-localizing SPECT-CT exam within the past year will be included. Subjects will be treated with calcitonin to lower calcium levels immediately prior to reimaging. The goal of this study is to determine whether lowering calcium will improve uptake/retention of sestamibi and improve sensitivity of SPECT-CT to localize parathyroid adenoma.

Conditions

Primary Hyperparathyroidism, Hypercalcemia

Talk to us

Study Overview

On this page

Study Details

Study overview

Patients with biochemically confirmed primary hyperparathyroidism and non-localizing SPECT-CT exam within the past year will be included. Subjects will be treated with calcitonin to lower calcium levels immediately prior to reimaging. The goal of this study is to determine whether lowering calcium will improve uptake/retention of sestamibi and improve sensitivity of SPECT-CT to localize parathyroid adenoma.

Improving the Sensitivity of Sestamibi SPECT-CT Parathyroid Scan with Calcitonin Pre-treatment for Primary Hyperparathyroidism

Calcitonin Pre-treatment to Improve SPECT-CT Sensitivity

Condition
Primary Hyperparathyroidism
Intervention / Treatment

-

Contacts and Locations

Toledo

ProMedica Toledo Hospital, Toledo, Ohio, United States, 43606

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • * Diagnosis of primary hyperparathyroidism
  • * Non-localizing SPECT-CT performed within 365 days prior to consent to participate in study
  • * Patient desires surgical intervention for treatment of PHPT
  • * No contraindications to 99mTC-Sestamibi
  • * No contraindications to treatment with calcitonin
  • * Serum calcium level prior to non-localizing SPECT-CT is ≥10.5 mg/dL
  • * Patient consents to participate and undergo second SPECT-CT for purposes of research
  • * Previous surgery to the neck, including resection of parathyroid tissue, except where end organ damage is present and further surgical intervention is medically necessary
  • * Contraindication to 99mTC-Sestamibi SPECT-CT as evidenced by allergic reaction or adverse event during index SPECT-CT
  • * Allergy to calcitonin
  • * Hypocalcemia (contraindication to calcitonin)
  • * Vitamin D deficiency (contraindication to calcitonin)
  • * Previous treatment with radioactive iodine
  • * New prescription of thyroid medication (levothyroxine, armour thyroid tablets, etc. must be taken at time of index scan and research scan)
  • * Lithium exposure within one year of SPECT-CT (index and research scans)
  • * Secondary hyperparathyroidism
  • * Benign familial hypocalciuric hypercalcemia
  • * Known malignancy, particularly multiple endocrine neoplasia
  • * New prescription of thiazide diuretic, (thiazide diuretic must have been taken at the time of index scan and second scan)
  • * Currently taking calcium channel blockers
  • * Pregnancy

Ages Eligible for Study

18 Years to

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

No

Collaborators and Investigators

Joseph Sferra,

Joseph Sferra, MD, PRINCIPAL_INVESTIGATOR, University of Toledo College of Medicine

Study Record Dates

2026-12-31